Regen BioPharma Inc RGBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGBP is a good fit for your portfolio.
News
-
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
-
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
-
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024
-
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
-
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
Trading Information
- Previous Close Price
- $0.70
- Day Range
- $0.65–0.70
- 52-Week Range
- $0.40–2.55
- Bid/Ask
- $0.41 / $0.80
- Market Cap
- $2.55 Mil
- Volume/Avg
- 11,730 / 15,923
Key Statistics
- Price/Earnings (Normalized)
- 2.26
- Price/Sales
- 10.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
Valuation
|
Metric
|
RGBP
|
|---|---|
Price/Earnings (Normalized) | 2.26 |
Price/Book Value | — |
Price/Sales | 10.64 |
Price/Cash Flow | — |
Price/Earnings
RGBP
Financial Strength
|
Metric
|
RGBP
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.03 |
Interest Coverage | −11.91 |
Quick Ratio
RGBP
Profitability
|
Metric
|
RGBP
|
|---|---|
Return on Assets (Normalized) | −273.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RGBP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lsxhwvmxrz | Tnxl | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xtytwrb | Dsqjswx | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Crltvrfd | Rxrlrbp | $98.1 Bil | |
MRNA
| Moderna Inc | Twrbxhdw | Dmdr | $39.1 Bil | |
ARGX
| argenx SE ADR | Hrqsmfxs | Yrxrh | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Pmcnyfhsg | Ygcw | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dvblsvhj | Vdxgkk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kyzxgngk | Zspbssn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xpznvnbkb | Tzrjwlf | $12.5 Bil | |
INCY
| Incyte Corp | Hybmmlt | Mzvhwy | $11.9 Bil |